United Therapeutics Corporation (UTH)
XDUS 
Summary
UTH Chart
UTHR Completes Phase III Tyvaso Study Enrollment for Expanded Label
United Therapeutics completes enrollment in its phase III study evaluating Tyvaso for an additional indication, PPF, with top-line results expected in the second half of 2027.
United Therapeutics Q2 Earnings Beat Estimates, Revenues Miss Mark
UTHR tops Q2 EPS estimates, misses revenues, while advancing Tyvaso and ralinepag programs that reshape future growth.
United Therapeutics Q2 Earnings Call Highlights
United Therapeutics NASDAQ: UTHR reported second-quarter 2026 revenue of approximately $783 million, essentially flat from the first quarter, as competitive pressure affected sales of its nebulized TYVASO therapy. Company executives said they expect stronger performance in the second half of the year but did not reaffirm or update previous 2026 revenue-growth expectations.
United Therapeutics Corporation (UTH) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has United Therapeutics Corporation ever had a stock split?
United Therapeutics Corporation Profile
| Biotechnology Industry | Healthcare Sector | Martine A. Rothblatt CEO | XDUS Exchange | US91307C1027 ISIN |
| US Country | 1,400 Employees | - Last Dividend | 23 Sep 2009 Last Split | 17 Jun 1999 IPO Date |
Overview
United Therapeutics Corporation is a biotechnology company that plays a pivotal role in developing and commercializing innovative therapies aimed at fulfilling the unmet medical needs of patients suffering from chronic and life-threatening diseases. The company operates globally, offering a range of treatments that target conditions such as pulmonary arterial hypertension (PAH) and high-risk neuroblastoma, among others. Founded in 1996, its headquarters are located in Silver Spring, Maryland. Through its research, United Therapeutics is dedicated to advancing medical science and improving the quality of life for patients around the world.
Products and Services
Listed below are United Therapeutics Corporation's key commercial therapies and projects under development:
- Remodulin: An injectable formulation of treprostinil designed to mitigate symptoms associated with exertion in patients with pulmonary arterial hypertension (PAH). It aims to improve the quality of life for those afflicted by this condition.
- Tyvaso: An inhaled form of treprostinil that seeks to enhance the exercise capacity of patients with PAH and those with pulmonary hypertension associated with interstitial lung disease (PH-ILD). This therapy facilitates a non-invasive method of treatment delivery.
- Orenitram: A tablet version of treprostinil that serves the purpose of increasing exercise ability in patients suffering from PAH. Orenitram represents the oral administration route for treprostinil, offering a different approach to manage the disease.
- Unituxin: This monoclonal antibody is utilized in treating high-risk neuroblastoma, a form of cancer that predominantly affects children and poses significant treatment challenges. Unituxin offers hope in the fight against this aggressive disease.
- Adcirca: An oral PDE-5 inhibitor indicated to improve exercise ability in PAH patients. By targeting the pathway involved in vascular contraction and relaxation, Adcirca provides another avenue for managing symptoms of PAH.
- Other notable mentions in development include Tyvaso DPI, a dry powder inhalation form of Tyvaso aimed at providing a more convenient delivery method; Remunity Pump, which delivers treprostinil subcutaneously with enhanced patient mobility; RemoPro and Ralinepag for PAH treatment, showcasing the company's ongoing commitment to innovating in this field; and Aurora-GT, a promising gene therapy approach for rebuilding damaged blood vessels in the lungs. Additionally, the ongoing Tyvaso PERFECT and TETON studies explore the potential benefits of Tyvaso in patients with WHO Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD).
United Therapeutics' dedication to advancing pulmonary hypertension treatment is further evidenced by its strategic partnerships with DEKA Research & Development Corp., MannKind Corporation, and Arena Pharmaceuticals, Inc., aimed at enhancing the delivery and efficacy of treprostinil and other therapeutic agents.
